| Alhemo™ (concizumab injection) is used for hemophilia B patients who have developed inhibitors, which prevent replacement factor IX therapies from working properly. Alhemo contains the active substance concizumab, which belongs to a group of medicines called monoclonal antibodies. The monoclonal antibody in Alhemo recognizes a protein (TFPI) that prevents clotting, and by binding to this protein concizumab helps to increase clotting and stop bleeding in hemophilia patients. It has been approved in Canada, but is still under FDA review in the US. For more info click here.